Navigation Links
Pharmatech Oncology Announces Completion of SBIR Grant Research

DENVER, Oct. 20, 2011 /PRNewswire/ -- Pharmatech Oncology announces completion of a phase I Small Business Innovative Research (SBIR) grant project, funded by the National Cancer Institute (NCI). 

The SBIR grant project evaluated Pharmatech Oncology's innovative enrollment model called Just-in-Time (JIT) to enroll cancer patients into clinical trials.  The JIT model is prioritized around detection of patients with qualifying diagnoses across many research practices. Patients who meet study entry criteria and have interest in receiving the investigational treatment are enrolled into the trial within two weeks through rapid regulatory activation of their care center as a study site.  JIT is a patient-focused approach designed to align clinical research with cancer patient care as it is currently delivered in the US.

The SBIR project evaluated the feasibility and efficiency of JIT in five separate studies, comparing the research performance of JIT-initiated sites to traditionally managed sites in retrospective analyses.  JIT demonstrated advantages in several important areas:

  • Higher patient enrollment rates (3.1x greater at six months)
  • Fewer non-enrolling sites (77% reduction)
  • Reduced time to first patient enrolled  (79-95% fewer days)
  • Lower administrative cost per site
  • No reduction of patient safety or data quality

"The SBIR phase I results have significant implications for the commercial development of the JIT model," remarked Dr. Matthew Wiener, Pharmatech founder.  "The positive impact on the clinical trials we've evaluated has been profound. With this essential validation of the methodology we are beginning to see awareness and adaptation of JIT increase among study centers and sponsors, which is critical to the growth of JIT as a commercial research solution." Pharmatech Oncology has submitted an application for a new SBIR grant to fund a phase II program with the aim to develop the JIT model further toward such commercialization.  Dr. Wiener comments, "Our vision for JIT is that any cancer patient and oncologist in any research-capable practice should have access to all appropriate treatment options, including clinical trials."

About Pharmatech Oncology, Inc.:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) with a focus on oncology clinical research. Through an organized network of cancer clinics, the Company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and on promoting the inclusion of clinical trials in the spectrum of patient treatment options.

For more information about Pharmatech, please visit

The project described was supported by Award Number R43CA144362 from the National Cancer institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

SOURCE Pharmatech Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Congratulates the 2010 Nobel Laureates in Chemistry
2. Quest PharmaTech Announces Formation of Clinical Advisory Panel
3. Pharmatech Oncology to Present at 46th Annual DIA Meeting
4. Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial
5. WuXi PharmaTech Files 2009 Annual Report on Form 20-F
6. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2009 Results
7. WuXi PharmaTech (NYSE: WX) Holds Its Third Life Science and Chemistry Awards Ceremony in Beijing
8. WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening
9. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
10. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
11. WuXi PharmaTech Announces Second-Quarter 2009 Results
Post Your Comments:
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):